"ENMD-2076 is a novel, orally-active antimitotic and antiangiogenic molecule." Can you add anything to this description? Thanks in advance.
Sentiment: Strong Buy
...here, let me help...you might add that its probabIlity of success is somewhere approaching that of finding a pig flying through a snowstorm in Hades!...HAW, HAW, HAW!!!...
Sentiment: Strong Sell
The fact that millions of dollars were just added to Entremed's coffers tell me the trials are going well. Also, Entremed has received a royalty payment from Celgene for thalomid. We shoud know the amount when the qtr report comes out.
ENMD-2076 demonstrated more robust activity against cell lines of the TNBC subtype compared to the luminal and HER2-amplified subtypes.